Targeting a key metabolic regulator in acute myeloid leukemia
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
['FUNDING_R01'] · VERSITI WISCONSIN, INC. · NIH-11010051
This study is looking at how a protein called SIRT5 helps blood cancer cells survive, with the hope of finding new ways to treat acute myeloid leukemia (AML) and improve outcomes for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VERSITI WISCONSIN, INC. (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11010051 on ClinicalTrials.gov |
What this research studies
This research investigates the role of SIRT5, a metabolic regulator, in acute myeloid leukemia (AML), a type of blood cancer with low survival rates. The study aims to identify new therapeutic targets by examining how AML cells depend on SIRT5 for survival, particularly in the protective environment of the bone marrow. By using advanced techniques like shRNA screening, researchers will test primary AML cells to understand their vulnerabilities and how they adapt to current treatments. The goal is to develop more effective therapies that can overcome resistance mechanisms in AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may not have responded well to existing therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in targeting metabolic regulators in cancer, suggesting that this approach could be effective, although the specific targeting of SIRT5 in AML is relatively novel.
Where this research is happening
MILWAUKEE, UNITED STATES
- VERSITI WISCONSIN, INC. — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEININGER, MICHAEL W. — VERSITI WISCONSIN, INC.
- Study coordinator: DEININGER, MICHAEL W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.